The Potential for Muscarinic Receptor Subtype-Specific Pharmacotherapy for Alzheimer's Disease
- 1 December 1991
- journal article
- review article
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 66 (12) , 1225-1237
- https://doi.org/10.1016/s0025-6196(12)62474-4
Abstract
No abstract availableKeywords
This publication has 95 references indexed in Scilit:
- Molecular pharmacology of muscarinic receptor heterogeneityLife Sciences, 1989
- The pontomesencephalotegmental cholinergic system does not degenerate in Alzheimer's diseaseNeuroscience Letters, 1989
- Brainstem afferents to the basal forebrain in the ratNeuroscience, 1988
- Stimulation of phosphatidylinositol (PI) turnover may mediate the muscarinic suppression of the M-current in hippocampal pyramidal cellsNeuroscience Letters, 1988
- Presynaptic M1 muscarinic receptor modulates spontaneous release of acetylcholine from rat basal forebrain slicesNeuroscience Letters, 1988
- Reduced number of [3H]nicotine and [3H]acetylcholine binding sites in the frontal cortex of Alzheimer brainsNeuroscience Letters, 1986
- Physostigmine restores3H-acetylcholine efflux from Alzheimer brain slices to normal levelJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1986
- Pharmacological alleviation of cholinergic lesion induced memory deficits in ratsLife Sciences, 1985
- The basal nucleus of Meynert in patients with progressive supranuclear palsyNeuroscience Letters, 1984
- Neuron loss in the nucleus basalis of meynert in parkinsonism‐dementia complex of GuamAnnals of Neurology, 1983